NEW YORK (TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP - Get Report), to discuss the company's new treatment.Kidron said there are three stages in which patients with Type II diabetes act to treat it: changing their diet and lifestyle, taking medicine orally, and finally, using insulin pumps or injections. Oramed has created an ingestible insulin pill that patients would take in the second stage of their process. By administering the drug early enough, Kidron said, the patient's need to use insulin injections or pumps would be postponed. He added that oral administration is much better than injection. By performing the latter, the insulin is injected directly into the bloodstream, whereas an ingestible pill goes first to the liver, which regulates the secretion of insulin into the bloodstream. Kidron concluded that it's an exciting time, as the company is expected to complete a Phase II trial for the drug by the end of the year, and is also working on a similar project for Type I diabetes. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
More from Opinion
Cisco's Hiccup Is an Opportunity as the Stock Goes on Sale
Cisco's outlook disappointed. But given the company's market dominance, robust balance sheet and enticing dividend yield, buying the stock for the long term when the market seems fearful of the short-term prospects may prove to be a smart move.
Cisco Is Priced Attractively Ahead of Its Earnings Report
Despite challenges in the service provider vertical, Cisco continues to showcase strong business fundamentals. With valuations reaching a low point, this could be the time to own shares ahead of a potential post-earnings rebound.
Disney's Earnings: All Is Well in the House of Mouse
Disney's strong fiscal fourth quarter results provide evidence that the company is riding the right trends in high-quality content creation, direct-to-consumer media distribution and strong consumer discretionary spending.
Alphabet's Share Price Weakness Is an Opportunity to Buy
Alphabet shares pulled back after a third quarter earnings miss that did not accurately reflect the strong performance of the underlying business.